Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) – HC Wainwright issued their FY2024 earnings per share estimates for shares of Aptose Biosciences in a report released on Wednesday, November 20th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($1.79) per share for the year. HC Wainwright currently has a “Buy” rating and a $2.00 target price on the stock. The consensus estimate for Aptose Biosciences’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Aptose Biosciences’ Q4 2024 earnings at ($0.35) EPS.
Separately, StockNews.com began coverage on Aptose Biosciences in a research note on Thursday, November 21st. They set a “hold” rating for the company.
Aptose Biosciences Stock Down 3.4 %
Shares of NASDAQ:APTO opened at $0.18 on Monday. The business has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.58. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.91. The company has a market cap of $3.22 million, a price-to-earnings ratio of -0.06 and a beta of 1.26.
Institutional Trading of Aptose Biosciences
An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp raised its position in Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) by 71.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. Institutional investors own 26.62% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- 3 Best Fintech Stocks for a Portfolio Boost
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Financial Services Stocks Investing
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- ETF Screener: Uses and Step-by-Step Guide
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
